Community Memorial Hospital chosen to participate in nationwide study

August 05, 2005
Santa Paula News

Community Memorial Hospital has been chosen as one of approximately 100 hospitals nationwide to participate in a study conducted by Guidant Corporation, using the ACCULINK Carotid Stent for the treatment of carotid artery disease.

Community Memorial Hospital has been chosen as one of approximately 100 hospitals nationwide to participate in a study conducted by Guidant Corporation, using the ACCULINK Carotid Stent for the treatment of carotid artery disease.Guidant’s ACCULINK Carotid Stent System is designed specifically for use in the carotid artery. It features a self-expanding; crush-resistant stent constructed of nickel-titanium (nitinol) on a rapid exchange (RX) platform and is designed for precise deployment in the carotid artery.Carotid artery stenting is a minimally invasive procedure in which a physician uses a combination of balloon angioplasty and a stent implant to unblock and reopen the carotid artery, a major supplier of blood to the brain, to help prevent strokes. “This system holds great promise as a new, exciting technique in treating carotid artery disease”, says Shawn Skillern, M.D. Dr. Skillern, a vascular surgeon at CMH, will be a participating physician in this study. He is a member of the California Cardiac Surgeons Medical Group, located in Ventura, comprised of nationally-renowned surgeons specializing in cardiac and vascular care.
Community Memorial Hospital was chosen by Guidant Corporation based on surgical experience in this area.“We are looking forward to our association with Guidant during these trials”, states Gary Wilde, CEO at Community Memorial Hospital. “We pride ourselves on the expertise of the physicians here at CMH, and we are pleased to continue to make available to our community the latest cutting-edge medical treatments.”Guidant Corporation is a world leader in the design and development of cardiovascular medical products. They are currently the only company who has been approved by the FDA to use this device.



Site Search

E-Subscribe

Subscribe

E-SUBSCRIBE
Call 805 525 1890 to receive the entire paper early. $50.00 for one year.

webmaster